心脏结节病多中心前瞻性队列研究 (CHASM-CS)
Recent data has shown that sarcoidosis, presenting initially with cardiac manifestations (CS) of either conduction system disease or cardiomyopathy and sustained VT, is not uncommon. A Canadian physician survey found that most physicians do not investigate for CS as a possibility in these situations. Thus many patients with clinically important CS are going un-diagnosed. A study from Finland showed that missing the diagnosis of CS in these patients' leads to significant mortality and morbidity.
There are no published clinical consensus guidelines on treatment of CS. Corticosteroid therapy is advocated by most experts. This is based on very modest data from small retrospective observational studies using variable definitions of clinical response. The effect of corticosteroid treatment on the clinical course of CS has not been studied in prospective studies and will be one of the aims of this project. Recent physician surveys regarding CS, in Canada and the US, found that current clinical practice varies widely. The 2008 American College of Cardiology/American Heart Association/Heart Rhythm society guidelines recommend implantation of a defibrillator (Class IIa recommendation) to prevent sudden cardiac death. The most recent Canadian device therapy guidelines do not mention CS.
A multi-center collaborative approach to study CS is greatly needed." The investigators propose exactly that i.e. a multi-center prospective cohort to start to answer clinical questions. The investigators have formed the CANADIAN CARDIAC SARCOIDOSIS RESEARCH GROUP. The group includes respirologists with an interest in sarcoidosis, cardiac electrophysiologists, cardiac imaging specialists with extensive experience in imaging of sarcoidosis and biostatisticians. The research will be in two phases; a registry of current diagnostic approaches, treatment and prognosis, and a randomized clinical trial of the effect of corticosteroid treatment on the clinical course of cardiac sarcoidosis.
研究概览
地位
地位
详细说明
Baseline assessment of Clinically Manifest CS patients consists of: history, echocardiogram, ECG, chest CT scan, FDG-PET scan, blood for biomarkers within 2 months of the PET scan, cardiac MRI and possibly a signal average ECG and biopsy (encouraged-either endomyocardial or extra-cardiac).
Follow-up and clinical management of clinically manifest patients diagnosed with CS will occur at 3-6 months with a repeat FDG-PET scan and blood biomarkers. Follow-up will then be annually with an echo and ECG. Treatment with steroids/immunosuppressants and device therapy will be at the discretion of the treating physician.
Baseline assessment of patients diagnosed with extra-cardiac sarcoidosis and being screened for CS consists of: history, echocardiogram, ECG, holter, chest CT scan, biopsy, and cardiac MRI (CMR). If the CMR is suggestive of CS the patient will be have a FDG-PET scan done and be followed as a Clinically Silent patient. They will be contacted every 2 years. If the CMR is negative the patient will be followed as a extra-cardiac sarcoidosis patient with no evidence of CS and be in the control group. They will be contacted at 5 years and at the time of study completion.
All patients will be followed until the last patient recruited has been followed for 4 years.
The occurrence of the primary and secondary outcomes will be assessed in treated and untreated patients.
There will be 2 imaging core labs. The PET core lab will be located at UOHI under the direction of Dr. Robert Beanlands. The CMR core lab will be under the direction of Dr. Mathias Friedrich (McGill University). All scans will be read in the core labs by physicians who are blinded to the clinical details of the patients.
The Biomarker core lab will be at The University of Ottawa Heart Institute under the leadership of Dr P Liu.
研究类型
研究类型
注册 (估计的)
注册
联系人和位置
学习联系方式
学习联系方式
- 姓名:Janine E Ryan, BA(H), CCRP
- 电话号码:17077 613-696-7000
- 邮箱:jryan@ottawaheart.ca
研究联系人备份
- 姓名:David Birnie, MD
- 电话号码:613-696-7269
- 邮箱:dbirnie@ottawaheart.ca
学习地点
-
-
Alberta
-
Calgary、Alberta、加拿大、T2N 2T9
- 招聘中
- Libin Cardiovascular Institute of Alberta
-
首席研究员:
- Russell Quinn, MD
-
接触:
- Russell Quinn, MD
-
Edmonton、Alberta、加拿大、T6G 2B7
- 招聘中
- University of Alberta Hospital
-
接触:
- Tomascz Hruczkowski, MD
-
首席研究员:
- Tomascz Hruczkowski, MD
-
-
British Columbia
-
Vancouver、British Columbia、加拿大、V5Z 1M9
- 招聘中
- St. Paul's Hospital
-
接触:
- Shanta Chakrabarti, MD
-
首席研究员:
- Shanta Chakrabarti, MD
-
-
Nova Scotia
-
Halifax、Nova Scotia、加拿大、B3H 3A7
- 招聘中
- QEII Health Sciences Center
-
首席研究员:
- Ciorsti MacIntyre, MD
-
接触:
- Kim Anderson, MD
-
-
Ontario
-
Hamilton、Ontario、加拿大、L8L 2X2
- 招聘中
- Hamilton Health Sciences Centre
-
首席研究员:
- Jeff Healey, MD
-
接触:
- Gerard Cox, MD
-
接触:
- Jeff Healey, MD
-
London、Ontario、加拿大、N6A 5A5
- 招聘中
- London Health Sciences Centre
-
接触:
- Lorne Gula, MD
-
首席研究员:
- Lorne Gula, MD
-
Newmarket、Ontario、加拿大、L3Y 2P9
- 招聘中
- Southlake Regional Health Centre
-
接触:
- Bernice Tsang, MD
-
首席研究员:
- Bernice Tsang, MD
-
Ottawa、Ontario、加拿大、K1Y 4W7
- 招聘中
- University of Ottawa Heart Institute
-
接触:
- Tammy Knight
- 电话号码:19080 613-696-7000
- 邮箱:tknight@ottawaheart.ca
-
首席研究员:
- David Birnie, MD
-
接触:
- Janine E Ryan, BA H
- 电话号码:17077 613-696-7000
- 邮箱:jryan@ottawaheart.ca
-
Toronto、Ontario、加拿大、M5G 2C4
- 招聘中
- Toronto General Hospital
-
接触:
- Andrew Ha, MD
-
首席研究员:
- Andrew Ha, MD
-
-
Quebec
-
Montreal、Quebec、加拿大、H1T 1C8
- 招聘中
- Montreal Heart Institute
-
接触:
- Lena Rivard, MD
-
首席研究员:
- Lena Rivard, MD
-
Montreal、Quebec、加拿大、H3G 1A4
- 招聘中
- McGill University Health Centre
-
接触:
- Fiorella Rafti
-
首席研究员:
- Martin L Bernier, MD
-
Montreal、Quebec、加拿大、H2W 1T8
- 尚未招聘
- Centre Hospitalier de l"Universite de Montreal-Hotel Dieu
-
接触:
- Julie Fleury, RN
-
首席研究员:
- Benoit Coutu, MD
-
-
Saskatchewan
-
Regina、Saskatchewan、加拿大、S4P 0W5
- 招聘中
- Prairie Vascular Research Inc-Regina General Hospital
-
接触:
- Kendra Townsend
- 邮箱:Ktownsend.pvri@gmail.com
-
首席研究员:
- Andrea Lavoie, MD
-
-
-
-
-
Sapporo、日本、060-8638
- 招聘中
- Hokkaido University
-
接触:
- Ichizo Tsujino, MD
- 电话号码:81-11-706-5911
- 邮箱:itsujino@med.hokudai.ac.jp
-
首席研究员:
- Ichizo Tsujino, MD
-
-
参与标准
资格标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Electrophysiology Service patients
描述
Inclusion Criteria:
To diagnose Clinically Manifest CS all following criteria must be met:
(i) Positive biopsy* for Sarcoid (either EMB or extra-cardiac) AND/OR (ii) CT Chest highly suggestive of pulmonary sarcoidosis AND (iii) one or more of the following clinical features:
- advanced conduction system disease (sustained Mobitz II AV block or third degree AV block)
- non- sustained or sustained ventricular arrhythmia
- ventricular dysfunction (LVEF < 50% and/or RVEF < 40%) AND (iv) No alternative explanation for clinical features AND (v) FDG-PET suggestive of active CS
To diagnose clinically silent CS all of the following criteria must be met
(i) Biopsy proven extra-cardiac sarcoidosis
AND/OR (ii) CT Chest highly suggestive of pulmonary sarcoidosis
AND (iii) CMR suggestive of cardiac sarcoidosis
AND (iv) Does not have criteria for clinically manifest CS ie. should not have any of following
- advanced conduction system disease (sustained Mobitz II AV block or third degree AV block)
- non- sustained or sustained ventricular arrhythmia
- ventricular dysfunction (LVEF < 50% and/or RVEF < 40%)
Patients with negative CMR will be designated as 'extra-cardiac sarcoidosis with no evidence of CS' and followed as control
Exclusion Criteria:
- unable or unwilling to provide informed consent
- patients who are pregnant or lactating
- patients with known claustrophobia
- age < 18 years
学习计划
研究是如何设计的?
设计细节
- 观测模型:COHORT
- 时间观点:PROSPECTIVE
团体/队列数
队列和干预
团体/队列团体/队列 |
|---|
|
CS screened as underlying etiology
|
研究衡量的是什么?
主要结果指标
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Primary Outcome for ALL Patients
大体时间:Through study completion, on average 10 years
|
The primary outcome is a composite of cardiac death, aborted sudden cardiac death, sustained ventricular arrhythmia, heart failure hospitalization or cardiac transplantation. Heart failure hospitalization is defined as admission to hospital > 24 hours and received treatment for heart failure. Primary and secondary endpoints will be assessed at various time intervals to be decided. |
Through study completion, on average 10 years
|
次要结果测量
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Secondary Outcomes for ALL Patients
大体时间:Through study completion, on average 10 years
|
1. Total mortality Primary and secondary endpoints will be assessed at various time intervals to be decided. |
Through study completion, on average 10 years
|
|
Secondary Outcomes for ALL Patients
大体时间:Through study completion, on average 10 years
|
2. Individual components of primary outcome (cardiac death, aborted sudden cardiac death, sustained ventricular arrhythmia, heart failure hospitalization or cardiac transplantation) Primary and secondary endpoints will be assessed at various time intervals to be decided. |
Through study completion, on average 10 years
|
|
Secondary Outcomes for Patients with Clinically Manifest Disease
大体时间:Through study completion, on average 10 years
|
1. Change in LVEF from baseline (%) Primary and secondary endpoints will be assessed at various time intervals to be decided. |
Through study completion, on average 10 years
|
|
Secondary Outcomes for Patients with Clinically Manifest Disease
大体时间:Through study completion, on average 10 years
|
2. Change in RVEF from baseline (%) Primary and secondary endpoints will be assessed at various time intervals to be decided. |
Through study completion, on average 10 years
|
|
Secondary Outcomes for Patients with Clinically Manifest Disease
大体时间:Through study completion, on average 10 years
|
3. Change in cardiac disease activity from pre-treatment to on treatment and post-treatment cessation as assessed by FDG-PET Primary and secondary endpoints will be assessed at various time intervals to be decided. |
Through study completion, on average 10 years
|
|
Secondary Outcomes for Patients with Clinically Manifest Disease
大体时间:Through study completion, on average 10 years
|
4. Atrial fibrillation burden (from ICD and/or pacemaker diagnostics) Primary and secondary endpoints will be assessed at various time intervals to be decided. |
Through study completion, on average 10 years
|
|
Secondary Outcomes for Patients with Clinically Manifest Disease
大体时间:Through study completion, on average 10 years
|
5. Ventricular arrhythmia burden, including PVC burden (from ICD diagnostics and/or pacemaker diagnostics) Primary and secondary endpoints will be assessed at various time intervals to be decided. |
Through study completion, on average 10 years
|
|
Secondary Outcomes for Patients with Clinically Manifest Disease
大体时间:Through study completion, on average 10 years
|
6. Appropriate ICD therapy Primary and secondary endpoints will be assessed at various time intervals to be decided. |
Through study completion, on average 10 years
|
|
Secondary Outcomes for Patients with Clinically Manifest Disease
大体时间:Through study completion, on average 10 years
|
7. Percentage (%) of ventricular pacing Primary and secondary endpoints will be assessed at various time intervals to be decided. |
Through study completion, on average 10 years
|
|
Secondary Outcomes for Patients with Clinically Manifest Disease
大体时间:Through study completion, on average 10 years
|
8. AV nodal function Primary and secondary endpoints will be assessed at various time intervals to be decided. |
Through study completion, on average 10 years
|
|
Secondary Outcomes for Patients with Clinically Silent Disease and Control Patients
大体时间:Through study completion, on average 10 years
|
1. Development of Clinically Manifest CS Primary and secondary endpoints will be assessed at various time intervals to be decided. |
Through study completion, on average 10 years
|
合作者和调查者
合作者
合作者
调查人员
调查人员
- 首席研究员:Pablo Nery, MD、Ottawa Heart Institute Research Corporation
- 首席研究员:Rob Beanlands, MD、Ottawa Heart Institute Research Corporation
- 首席研究员:David Birnie, MD、Ottawa Heart Institute Research Corporation
出版物和有用的链接
一般刊物
- Weng W, Wiefels C, Chakrabarti S, Nery PB, Celiker-Guler E, Healey JS, Hruczkowski TW, Quinn FR, Promislow S, Medor MC, Spence S, Odabashian R, Alqarawi W, Juneau D, de Kemp R, Leung E, Beanlands R, Birnie D. Atrial Arrhythmias in Clinically Manifest Cardiac Sarcoidosis: Incidence, Burden, Predictors, and Outcomes. J Am Heart Assoc. 2020 Sep;9(17):e017086. doi: 10.1161/JAHA.120.017086. Epub 2020 Aug 20.
- Martineau P, Pelletier-Galarneau M, Juneau D, Leung E, Nery PB, de Kemp R, Beanlands R, Birnie D. Imaging Cardiac Sarcoidosis With FLT-PET Compared With FDG/Perfusion-PET: A Prospective Pilot Study. JACC Cardiovasc Imaging. 2019 Nov;12(11 Pt 1):2280-2281. doi: 10.1016/j.jcmg.2019.06.020. Epub 2019 Aug 14. No abstract available.
研究记录日期
研究主要日期
学习开始 (实际的)
学习开始
初级完成 (估计的)
初级完成
研究完成 (估计的)
研究完成
研究注册日期
首次提交
首次提交
首先提交符合 QC 标准的
首先提交符合 QC 标准的
首次发布 (估计的)
首次发布
研究记录更新
最后更新发布 (实际的)
最后更新发布
上次提交的符合 QC 标准的更新
上次提交的符合 QC 标准的更新
最后验证
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.